Abstract 1597P
Background
Cancer is the leading cause of death in Ireland, accounting for 28.5% of all deaths in 2021. Our aging population is predicted to drive a significant increase in new cancer cases in the coming decades. As such, high quality end-of-life care (EOLC) for patients dying in the acute hospital setting is an essential part of delivering holistic care to patients with cancer and their families. This is the second audit cycle to examine the quality of EOLC in one of the largest university teaching hospitals in Ireland. The first audit cycle, during the COVID-19 pandemic, identified several shortcomings in EOLC ( ESMO 2022 : S1134).
Methods
A care of dying patients guidance document, EOLC quality checklist, and staff education huddles facilitated by the Hospital Palliative Care Team were introduced in July 2022. A second retrospective chart review of patients who died under the care of the medical oncology service between 11th July 2022 and 30th April 2023 was performed. Data on the quality of EOLC delivered was collected and assessed using the published Oxford Quality Indicators for mortality review. An overall score for EOLC between 1 (very poor) and 5 (excellent) was assigned to each patient. These were compared with the previously presented 2021 cohort.
Results
We identified 72 patients (41 female). The median age at death was 65 years [23-89]. The mean length of admission resulting in death was 15.2 days [0-118]. The mean quality score for EOLC was 4.0, compared to 3.5 pre-intervention. Exploration of patient wishes, and spiritual care were documented in 45.8% and 58.3% of cases respectively, compared to 24.2% and 10.6% in the initial audit. 42 patients (58.3%) had care of the dying patient documents completed. The mean quality score for EOLC for these patients was 4.6, versus 3.2 for those without the document.
Conclusions
The quality of EOLC in our organisation has improved numerically in the second audit cycle. Areas of ongoing non-compliance to the Oxford Quality Indicators include exploration of patient wishes and spiritual care. The end-of-life committee, which now includes doctors in training, is committed to continuing to address deficits in the quality of EOLC in our institution, as an ESMO Designated Centre of Integrated Oncology and Palliative Care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05